- Home
- JAGX vs SONN Comparison
JAGX vs SONN Comparison
Compare JAGX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- SONN
- Stock Information
- Founded
- JAGX 2013
- SONN N/A
- Country
- JAGX United States
- SONN United States
- Employees
- JAGX N/A
- SONN N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- SONN Health Care
- Exchange
- JAGX Nasdaq
- SONN Nasdaq
- Market Cap
- JAGX 3.4M
- SONN 3.8M
- IPO Year
- JAGX N/A
- SONN N/A
- Fundamental
- Price
- JAGX $2.35
- SONN $2.99
- Analyst Decision
- JAGX Strong Buy
- SONN Strong Buy
- Analyst Count
- JAGX 1
- SONN 1
- Target Price
- JAGX $60.00
- SONN $20.00
- AVG Volume (30 Days)
- JAGX 75.4K
- SONN 998.0K
- Earning Date
- JAGX 08-14-2025
- SONN 08-18-2025
- Dividend Yield
- JAGX N/A
- SONN N/A
- EPS Growth
- JAGX N/A
- SONN N/A
- EPS
- JAGX N/A
- SONN N/A
- Revenue
- JAGX $11,552,000.00
- SONN $1,000,000.00
- Revenue This Year
- JAGX $22.41
- SONN $5,376.22
- Revenue Next Year
- JAGX $30.00
- SONN N/A
- P/E Ratio
- JAGX N/A
- SONN N/A
- Revenue Growth
- JAGX 13.93
- SONN 978.39
- 52 Week Low
- JAGX $1.93
- SONN $1.08
- 52 Week High
- JAGX $35.25
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- JAGX 46.26
- SONN 43.44
- Support Level
- JAGX $2.02
- SONN $2.75
- Resistance Level
- JAGX $2.33
- SONN $3.59
- Average True Range (ATR)
- JAGX 0.14
- SONN 0.51
- MACD
- JAGX 0.07
- SONN -0.20
- Stochastic Oscillator
- JAGX 58.33
- SONN 19.84
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.